Skip to main content
. Author manuscript; available in PMC: 2009 Aug 28.
Published in final edited form as: Brain Res. 2008 Jun 21;1227:198–206. doi: 10.1016/j.brainres.2008.06.046

Figure 1. Effect of KATP potassium channel agonists (KCO912, MS) on tumor permeability.

Figure 1

The regional Ki values in 9L tumors are calculated for different treatments and expressed as the percentage over that of control (% of control). The data represent mean ± SD. Refer to the results for Ki values. Potassium channel agonists and bradykinin were infused for 15 minutes with permeability determined at the 5 to 15-minute time interval, as described in the method. Bradykinin treatment served as the positive control. A, Treatments of KCO912 and MS in 9L/Wistar; C, Treatments of KCO912 and MS in 9L/Fischer; C, Treatments of KCO912 and glybenclamide in 9L/Wistar. BK, bradykinin; MS, minoxidil sulfate. The P values represent the comparisons to the control.